← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Navega Therapeutics, Inc.
San Diego, CA
$8,348,359
Total funding
7
Grants
Funding over time
peak $2.1M · FY2019–25$2.5M$1.9M$1.3M$625K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,348,359 · 7
By mechanism
U44$4,279,361 · 1
R44$2,183,954 · 1
R43$1,485,044 · 4
SB1$400,000 · 1
Investigators at Navega Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Preclinical optimization of a gene therapy for erythromelalgia and chronic pain$1,528,057
U44 · FY2024 · NS
Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels$1,283,183
R44 · FY2022 · CA
Preclinical optimization of a gene therapy for erythromelalgia and chronic pain$1,149,467
U44 · FY2023 · NS
Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels$766,685
R44 · FY2021 · CA
Preclinical optimization of a gene therapy for erythromelalgia and chronic pain$730,264
U44 · FY2022 · NS
Preclinical optimization of a gene therapy for erythromelalgia and chronic pain$698,171
U44 · FY2021 · NS
Repression of Sodium Channels via a Gene Therapy for Treatment of Chronic Neuropathic Pain$529,006
R43 · FY2019 · NS
Advancing precision pain medicines to the clinic$400,000
SB1 · FY2023 · NS
Reformulating NT-Z001 and its delivery route to treat rheumatoid arthritis$297,327
R43 · FY2025 · AR
Treatment of Chemotherapy-Induced Peripheral Neuropathy via Genetic Repression of Sodium Channels$288,284
R43 · FY2019 · CA
Optimization of a Gene Therapy for Chronic Pain in Human DRGs$275,377
R43 · FY2021 · NS
Supplement to Promote Diversity, Inclusion, and Career Development of a Female Scientist$134,086
R44 · FY2022 · CA
Preclinical optimization of a gene therapy for erythromelalgia and chronic pain$98,701
U44 · FY2024 · NS
Supplement to Promote Diversity and Inclusion, Female Scientist$95,050
R43 · FY2020 · NS
Preclinical optimization of a gene therapy for erythromelalgia and chronic pain$74,701
U44 · FY2024 · NS